Portfolio Holdings Detail for ISIN IE00019GPKX6

Stock Name / Fund	iShares MSCI ACWI UCITS ETF SGD Hedged (Acc)
Issuer	Blackrock
Entity holding fund	iShares V Public Limited Company
Entity Type
Entity LEI	549300QETNU1W5JY7Z94
ETF Ticker	ISGDx(SGD) CXE

Holdings detail for LEGN

Show aggregate LEGN holdings

News associated with LEGN

Brokerages Set Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Price Target at $74.22

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month price […] - 2025-09-19 02:43:01

Legend Biotech Becomes Oversold (LEGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me - 2025-09-10 14:53:11

JPMorgan Chase & Co. Increases Legend Biotech (NASDAQ:LEGN) Price Target to $78.00

Legend Biotech (NASDAQ:LEGN – Get Free Report) had its price target raised by research analysts at JPMorgan Chase & Co. from $77.00 to $78.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of […] - 2025-08-27 02:30:45

Legend Biotech Breaks Below 200-Day Moving Average - Notable for LEGN

In trading on Monday, shares of Legend Biotech Corp (Symbol: LEGN) crossed below their 200 day moving average of $36.28, changing hands as low as $35.23 per share. Legend Biotech Corp shares are currently trading off about 2.5% on the day. The chart below shows the one year pe - 2025-08-11 12:46:01

Legend Biotech (NASDAQ:LEGN) Rating Increased to Strong-Buy at Cantor Fitzgerald

Legend Biotech (NASDAQ:LEGN – Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports. Other equities research analysts also recently issued research reports about the company. Johnson Rice reissued a “buy” rating on shares of Legend Biotech in a research report on […] - 2025-08-06 03:12:50

GAMMA Investing LLC Boosts Position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN)

GAMMA Investing LLC increased its holdings in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) by 145.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,291 shares of the company’s stock after purchasing an additional 765 […] - 2025-07-11 04:12:51

Legend Biotech (NASDAQ:LEGN) Receives Buy Rating from HC Wainwright

Legend Biotech (NASDAQ:LEGN – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $75.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 90.07% from the company’s previous close. A number of other […] - 2025-07-10 04:01:26

Rhumbline Advisers Purchases 391 Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN)

Rhumbline Advisers lifted its position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) by 1.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,029 shares of the company’s stock after acquiring an additional 391 shares during the quarter. Rhumbline Advisers’ holdings […] - 2025-06-20 04:25:11

Thursday's ETF with Unusual Volume: FTQI

The First Trust Nasdaq BuyWrite Income ETF is seeing unusually high volume in afternoon trading Thursday, with over 909,000 shares traded versus three month average volume of about 226,000. Shares of FTQI were down about 0.2% on the day. Components of that ETF with the highest - 2025-06-12 15:09:39

Tuesday's ETF with Unusual Volume: EEMA

The iShares MSCI Emerging Markets Asia ETF is seeing unusually high volume in afternoon trading Tuesday, with over 2.5 million shares traded versus three month average volume of about 92,000. Shares of EEMA were up about 0.3% on the day. Components of that ETF with the highest - 2025-06-10 14:57:32

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 36,181 Shares of Legend Biotech Co. (NASDAQ:LEGN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 36.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 136,438 shares of the company’s stock after […] - 2025-06-04 05:02:51

Nuveen Asset Management LLC Acquires 5,700 Shares of Legend Biotech Co. (NASDAQ:LEGN)

Nuveen Asset Management LLC grew its holdings in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 5.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 110,586 shares of the company’s stock after purchasing an additional 5,700 shares during the period. Nuveen Asset Management LLC’s […] - 2025-06-02 05:04:55

Legend Biotech Co. (NASDAQ:LEGN) Shares Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC grew its holdings in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 44.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 127,900 shares of the company’s stock after acquiring an additional 39,197 shares during the quarter. Squarepoint Ops […] - 2025-05-27 05:13:00

Millennium Management LLC Has $8.31 Million Holdings in Legend Biotech Co. (NASDAQ:LEGN)

Millennium Management LLC lessened its stake in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 55.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 255,468 shares of the company’s stock after selling 314,908 shares during the quarter. Millennium Management LLC’s […] - 2025-05-26 04:42:54

Deutsche Bank AG Acquires 14,198 Shares of Legend Biotech Co. (NASDAQ:LEGN)

Deutsche Bank AG lifted its holdings in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 11.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 135,067 shares of the company’s stock after acquiring an additional 14,198 shares during the period. Deutsche Bank […] - 2025-05-20 05:12:55

Legend Biotech (NASDAQ:LEGN) Hits New 12-Month Low After Analyst Downgrade

Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) hit a new 52-week low during mid-day trading on Thursday after Truist Financial lowered their price target on the stock from $88.00 to $71.00. Truist Financial currently has a buy rating on the stock. Legend Biotech traded as low as $27.54 and last traded at […] - 2025-05-16 03:02:47

Legend Biotech Co. (NASDAQ:LEGN) Stake Boosted by Stifel Financial Corp

Stifel Financial Corp increased its position in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 70.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,365 shares of the company’s stock after acquiring an additional 12,955 shares […] - 2025-05-09 05:58:54

Zurcher Kantonalbank Zurich Cantonalbank Trims Position in Legend Biotech Co. (NASDAQ:LEGN)

Zurcher Kantonalbank Zurich Cantonalbank decreased its position in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 18.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 40,913 shares of the company’s stock after selling 9,355 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Legend […] - 2025-03-19 05:40:51

Morgan Stanley Issues Pessimistic Forecast for Legend Biotech (NASDAQ:LEGN) Stock Price

Legend Biotech (NASDAQ:LEGN – Get Free Report) had its target price dropped by analysts at Morgan Stanley from $82.00 to $80.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s target price points to a potential upside of 111.19% from the company’s current […] - 2025-03-19 04:28:56

Daiwa Securities Group Inc. Raises Stock Position in Legend Biotech Co. (NASDAQ:LEGN)

Daiwa Securities Group Inc. lifted its holdings in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 165.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 8,516 shares of the company’s stock after acquiring an additional 5,309 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Legend Biotech were worth $278,000 as […] - 2025-03-17 06:06:55

Company News for Mar 12, 2025

Companies in The News Are: FRG, ORCL, LEGN, PAY - 2025-03-12 11:20:00

Legend Biotech Co. (NASDAQ:LEGN) Receives $79.50 Average PT from Brokerages

Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) have been given a consensus rating of “Buy” by the twelve research firms that are covering the stock, MarketBeat Ratings reports. Twelve analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued ratings on the stock […] - 2025-03-03 04:50:55

Legend Biotech Co. (NASDAQ:LEGN) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lowered its stake in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 173,766 shares of the company’s stock after selling 3,461 shares during the quarter. Sumitomo Mitsui Trust […] - 2025-02-14 07:35:09

Contrasting Legend Biotech (NASDAQ:LEGN) and COMPASS Pathways (NASDAQ:CMPS)

COMPASS Pathways (NASDAQ:CMPS – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Earnings & Valuation This table compares COMPASS Pathways […] - 2025-02-06 04:06:58

How The Parts Add Up: KOMP Headed For $62

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-02-04 10:28:33

iShares MSCI ACWI UCITS ETF SGD Hedged (Acc) LEGN holdings

Date	Number of LEGN Shares Held	Base Market Value of LEGN Shares	Local Market Value of LEGN Shares	Change in LEGN Shares Held	Change in LEGN Base Value	Current Price per LEGN Share Held	Previous Price per LEGN Share Held
2025-09-18 (Thursday)	17,956	USD 631,333	USD 631,333	0	USD 12,390	USD 35.16	USD 34.47
2025-09-17 (Wednesday)	17,956	USD 618,943	USD 618,943	0	USD 2,334	USD 34.47	USD 34.34
2025-09-16 (Tuesday)	17,956	USD 616,609	USD 616,609	0	USD 8,260	USD 34.34	USD 33.88
2025-09-15 (Monday)	17,956	USD 608,349	USD 608,349
2025-09-12 (Friday)	17,875	USD 591,841	USD 591,841
2025-09-11 (Thursday)	17,875	USD 604,711	USD 604,711
2025-09-10 (Wednesday)	17,875	USD 598,276	USD 598,276
2025-09-09 (Tuesday)	17,875	USD 612,219	USD 612,219
2025-09-08 (Monday)	17,794	USD 616,028	USD 616,028

Share Trades of LEGN by Blackrock for IE00019GPKX6

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-09-04	BUY	108			34.990*		36.41
2025-08-19	BUY	63			36.540*		36.41
2025-07-25	BUY	36			43.360*		36.36
2025-07-22	BUY	45			44.020*		36.21
2025-07-14	BUY	27			39.440*		36.07
2025-07-10	BUY	54			39.710*		36.02
2025-07-08	BUY	27			37.490*		35.99
2025-07-02	BUY	45			35.910*		36.00
2025-06-25	BUY	9			33.430*		36.04
2025-06-12	BUY	81			37.910*		36.10
2025-06-02	BUY	108			29.320*		36.30
2025-05-28	BUY	27			28.290*		36.49
2025-05-14	BUY	27			27.800*		37.21
2025-05-08	BUY	45			32.040*		37.41
2025-05-07	BUY	144			31.470*		37.47
2025-04-30	BUY	27			34.950*		37.67
2025-04-24	BUY	9			34.240*		37.81
2025-04-23	BUY	72			34.300*		37.84
2025-04-17	BUY	36			32.800*		38.05
2025-04-16	BUY	18			33.460*		38.10
2025-04-15	BUY	18			33.740*		38.15
2025-04-14	BUY	54			32.110*		38.22
2025-04-11	BUY	144			32.000*		38.29
2025-04-10	BUY	81			31.280*		38.38
2025-04-09	BUY	45			32.080*		38.45
2025-04-08	BUY	45			30.770*		38.54
2025-04-07	BUY	36			30.250*		38.64
2025-04-04	BUY	45			32.010*		38.72
2025-04-02	BUY	36			33.240*		38.79
2025-03-28	BUY	36			35.060*		38.99
2025-03-24	BUY	18			36.330*		39.19
2025-03-18	BUY	27			37.880*		39.28
2025-03-17	BUY	45			37.940*		39.30
2025-03-14	BUY	36			37.200*		39.33
2025-03-13	BUY	81			38.050*		39.35
2025-03-10	BUY	27			34.030*		39.48
2025-03-04	BUY	36			33.980*		39.72
2025-02-25	BUY	36			37.010*		40.08
2025-02-21	BUY	36			39.700*		40.14
2025-02-19	BUY	36			38.750*		40.20
2025-02-18	BUY	36			38.220*		40.23
2025-02-13	BUY	27			36.390*		40.47
2025-02-12	BUY	18			35.870*		40.57
2025-02-11	BUY	36			34.630*		40.70
2025-02-05	BUY	27			37.770*		41.12
2025-02-03	BUY	72			37.310*		41.30
2025-01-31	BUY	27			38.100*		41.38
2025-01-30	BUY	27			37.220*		41.49
2025-01-28	BUY	27			36.010*		41.80
2025-01-02	BUY	162			34.730*		42.46
2024-12-10	BUY	27			37.900*		42.61
2024-12-03	SELL	-54			43.680*		42.68 Profit of 2,305 on sale
2024-11-20	BUY	72			40.140*		43.06
2024-11-19	BUY	27			38.400*		43.35
2024-11-18	BUY	18			37.420*		43.75
2024-11-07	BUY	63			40.950*		44.25
2024-10-30	BUY	27			44.270*		44.57
2024-10-28	BUY	9			45.300*		44.25
2024-10-22	BUY	45			45.035*		43.45

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of LEGN

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer